HK1032206A1 - Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function. - Google Patents

Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function.

Info

Publication number
HK1032206A1
HK1032206A1 HK01102854A HK01102854A HK1032206A1 HK 1032206 A1 HK1032206 A1 HK 1032206A1 HK 01102854 A HK01102854 A HK 01102854A HK 01102854 A HK01102854 A HK 01102854A HK 1032206 A1 HK1032206 A1 HK 1032206A1
Authority
HK
Hong Kong
Prior art keywords
threonine protein
azabenzimidazole
protein kinase
serine
based compounds
Prior art date
Application number
HK01102854A
Other languages
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Heinz Weinberger
Harald App
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HK1032206A1 publication Critical patent/HK1032206A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK01102854A 1997-09-26 2001-04-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function. HK1032206A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (1)

Publication Number Publication Date
HK1032206A1 true HK1032206A1 (en) 2001-07-13

Family

ID=22027657

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01102854A HK1032206A1 (en) 1997-09-26 2001-04-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function.

Country Status (28)

Country Link
US (2) US6093728A (pt)
EP (1) EP1017384B1 (pt)
JP (1) JP2001517699A (pt)
KR (1) KR100547929B1 (pt)
CN (1) CN1167420C (pt)
AR (1) AR017266A1 (pt)
AT (1) ATE281834T1 (pt)
AU (1) AU748849B2 (pt)
BG (1) BG64784B1 (pt)
BR (1) BR9812682A (pt)
CA (1) CA2305370C (pt)
DE (1) DE69827516T2 (pt)
DK (1) DK1017384T3 (pt)
ES (1) ES2230719T3 (pt)
HK (1) HK1032206A1 (pt)
HU (1) HUP0004024A3 (pt)
IL (4) IL135109A0 (pt)
NO (1) NO325663B1 (pt)
NZ (2) NZ503432A (pt)
PL (1) PL191618B1 (pt)
PT (1) PT1017384E (pt)
RU (1) RU2230553C2 (pt)
SK (1) SK285357B6 (pt)
TR (1) TR200001546T2 (pt)
TW (1) TW581815B (pt)
UA (1) UA72448C2 (pt)
WO (1) WO1999016438A1 (pt)
ZA (1) ZA988797B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
DK1368028T3 (da) * 2001-03-12 2007-12-27 Avanir Pharmaceuticals Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2630920A1 (en) 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7951819B2 (en) 2006-04-26 2011-05-31 Cancer Research Technology Limited Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
JP5513118B2 (ja) 2006-10-19 2014-06-04 シグナル ファーマシューティカルズ，エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
EP2839839B1 (en) * 2007-02-28 2018-01-17 Yeda Research And Development Company Limited Nuclear targeting sequences
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
WO2009077766A1 (en) 2007-12-19 2009-06-25 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010025448A2 (en) * 2008-08-29 2010-03-04 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011053518A1 (en) 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
EA034512B1 (ru) 2011-10-19 2020-02-14 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение злокачественной опухоли ингибиторами tor-киназы
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
AU2013202305B2 (en) 2012-02-24 2015-03-12 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014207641A1 (en) 2013-01-16 2015-08-06 Signal Pharmaceuticals, Llc Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
EP2970277B1 (en) 2013-03-15 2021-07-28 Knopp Biosciences LLC Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
CN105324381A (zh) 2013-04-17 2016-02-10 西格诺药品有限公司 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3046929B1 (en) 2013-09-17 2019-01-16 Yeda Research and Development Co., Ltd. Erk-derived peptides and uses thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
HUE064331T2 (hu) 2014-09-12 2024-03-28 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il amidok mint KV7 csatorna aktivátorok
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
EP0526488B1 (en) * 1990-04-02 1994-11-30 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) * 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
CZ283965B6 (cs) * 1992-08-06 1998-07-15 Warner-Lambert Company 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
HUP0004024A3 (en) 2001-10-29
ATE281834T1 (de) 2004-11-15
NO20001555L (no) 2000-03-24
AR017266A1 (es) 2001-09-05
CA2305370C (en) 2006-11-28
US20030181480A1 (en) 2003-09-25
IL135109A (en) 2007-07-04
BG64784B1 (bg) 2006-04-28
BG104356A (en) 2000-12-29
ES2230719T3 (es) 2005-05-01
TR200001546T2 (tr) 2000-10-23
CN1278172A (zh) 2000-12-27
IL158649A (en) 2006-12-10
PL191618B1 (pl) 2006-06-30
BR9812682A (pt) 2000-08-22
KR100547929B1 (ko) 2006-02-02
DK1017384T3 (da) 2005-01-31
SK4152000A3 (en) 2002-02-05
JP2001517699A (ja) 2001-10-09
IL158649A0 (en) 2004-05-12
DE69827516D1 (de) 2004-12-16
PL339744A1 (en) 2001-01-02
CA2305370A1 (en) 1999-04-08
AU748849B2 (en) 2002-06-13
US6855723B2 (en) 2005-02-15
NO20001555D0 (no) 2000-03-24
WO1999016438A1 (en) 1999-04-08
HUP0004024A2 (hu) 2001-04-28
US6093728A (en) 2000-07-25
CN1167420C (zh) 2004-09-22
NZ517808A (en) 2003-07-25
EP1017384B1 (en) 2004-11-10
UA72448C2 (en) 2005-03-15
KR20010015623A (ko) 2001-02-26
TW581815B (en) 2004-04-01
EP1017384A1 (en) 2000-07-12
DE69827516T2 (de) 2005-12-01
SK285357B6 (sk) 2006-11-03
IL135109A0 (en) 2001-05-20
AU9578198A (en) 1999-04-23
ZA988797B (en) 1999-12-02
NZ503432A (en) 2002-11-26
NO325663B1 (no) 2008-07-07
RU2230553C2 (ru) 2004-06-20
PT1017384E (pt) 2005-03-31

Similar Documents

Publication Publication Date Title
HK1032206A1 (en) Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function.
MXPA03011007A (es) Metodos para modular la funcion de serina/treonona proteina cinasa por compuestos basados en 5-azaquinoxalina.
WO2002096867A3 (en) Inhibitors of protein kinase for the treatment of disease
CA2122338A1 (en) Novel human cdc25 genes, encoded products and uses therefor
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MXPA01006742A (es) Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
WO2003086279A3 (en) Inhibitors of akt activity
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
GB9903762D0 (en) Organic compounds
NZ516292A (en) Pyrrolotriazine inhibitors of kinases
NZ503828A (en) Aminothiazole inhibitors of cyclin dependent kinases
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
IL138723A (en) Composition containing cisplatin and stilbene for treatment of tumors
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
BG101110A (en) Substituted pyrimidine compounds and their application
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
BR0016547A (pt) Composição para a modulação e inibição da permeabilidade vascular (vp)
MY105187A (en) Liquid detergent composition containing enzyme and stabilization system
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
WO2002036578A3 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
CA2343099A1 (en) Role of human kis (hkis) as an inhibitory kinase of the cyclin-dependentkinase inhibitor p27. compositions, methods and uses thereof to control cell proliferation
DK162839C (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og 3-acyl-2-oxindol-forbindelser til anvendelse som mellemprodukter ved deres fremstilling
DE3361276D1 (en) Cyano compounds useful as uv stabilizers for pc, and pc compositions and substrates stabilized therewith

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080923